Related Experiment Video
Updated: Jan 9, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Clotrimazole as a new frontier: Drug repurposing and its efficacy in cancer therapy
Shubham C Karpe1,2, Manjula Kiran1, Sukhen Majhi1
1Vaccine and Antisera Laboratory, National Institute of Biologicals, Plot No. A-32, Sector-62, Noida, Uttar Pradesh-201309, India.
Abstract:
Cancer, ranging from early stages to metastatic spread, is one of the leading causes of death globally. Current treatment options, including chemotherapy, radiotherapy, and targeted drugs, have limitations, such as significant side effects, drug resistance, and high cost. To overcome these challenges, extensive studies have explored the anticancer potential of various drugs such as clotrimazole (CLZ), which has shown promising anticancer effects. CLZ was first developed as an antifungal agent. Recently significant anticancer effects have been observed making it a suitable candidate for drug repurposing. Compared with other azole-based antifungals, CLZ has shown distinct therapeutic effects on cancer cells via several pathways. Its ability to disrupt glycolysis by inhibiting phosphofructokinase (PFK) and hexokinase (HK) distinguishes it from other azoles. Furthermore, CLZ obstructs calcium homeostasis and critical survival pathways, such as extracellular signal-regulated kinase (ERK)-p65, phosphatidylinositol 3-kinase (PI3K), and mitochondrial apoptotic pathways, inhibiting tumor growth, inducing apoptosis, and attenuating metastasis. This review explores the potential of repurposing CLZ in cancer and its well-established safety profile and cost-effectiveness to highlight current treatment gaps. It briefly examines in vitro and in vivo assessments to understand the mechanisms and effects of CLZ on various cancer types. Furthermore, novel strategies such as nanoformulations and combination therapies with existing chemotherapeutic drugs have been highlighted to improve therapeutic outcomes. Preclinical studies have provided promising evidence for the efficacy of CLZ in different cancers, showing tumor regression and improved responses to conventional chemotherapy or targeted therapies. Given its evident preclinical results and diverse mechanisms of action, CLZ may be considered an antineoplastic agent. Further clinical research is required to fully elucidate its anticancer potential, potentially positing it as a valuable addition to currently available cancer treatments.
More Related Videos
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Inhibition of Cdk Activity
Tumor Immunotherapy